tiprankstipranks
Trending News
More News >
Airsculpt Technologies, Inc. (AIRS)
:AIRS
US Market
Advertisement

Airsculpt Technologies (AIRS) AI Stock Analysis

Compare
58 Followers

Top Page

AIRS

Airsculpt Technologies

(NASDAQ:AIRS)

Rating:55Neutral
Price Target:
$6.00
▼(-0.50% Downside)
Airsculpt Technologies' stock score is primarily impacted by its financial performance, which exhibits weakness due to declining revenues and profitability. While technical analysis provides some positive signs, the valuation remains unattractive due to ongoing losses. The earnings call adds a mix of challenges and strategic improvements, but the overall score reflects existing financial pressures.
Positive Factors
Debt Management
The equity financing resolves the mandatory $10m debt repayment under its existing credit commitment.
Revenue Growth
There are encouraging signs with monthly sequential case growth and an increase in lead volume.
Negative Factors
Financial Flexibility
Leverage covenants tighten in the second half of 2025, which could impact financial flexibility.
Liquidity
Liquidity remains tight with no revolver capacity and only $5.6m in cash.
Volume Pressure
Volume is under pressure with SS revenues and cases declining to historically low levels.

Airsculpt Technologies (AIRS) vs. SPDR S&P 500 ETF (SPY)

Airsculpt Technologies Business Overview & Revenue Model

Company DescriptionAirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. It offers custom body contouring using its AirSculpt procedure that removes unwanted fat in a minimally invasive procedure. The company provides fat removal procedures across treatment areas; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. Its body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. As of March 10, 2022, it operated 19 centers across 15 states. AirSculpt Technologies, Inc. was founded in 2012 and is headquartered in Miami Beach, Florida.
How the Company Makes MoneyAirsculpt Technologies makes money primarily through the provision of its proprietary body contouring services. The company generates revenue by performing AirSculpt procedures at its network of clinics, which are strategically located to serve a broad client base. Key revenue streams include procedure fees paid by patients seeking body sculpting treatments. Additionally, the company may benefit from partnerships with healthcare providers or aesthetic clinics that offer its services as part of their portfolio. Other factors contributing to its earnings could include patient referrals, repeat business from satisfied clients, and expansion into new geographic markets.

Airsculpt Technologies Earnings Call Summary

Earnings Call Date:Aug 01, 2025
(Q2-2025)
|
% Change Since: -8.77%|
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
While AirSculpt Technologies made progress in lead growth, debt reduction, and cost management, the company faced significant revenue and case volume declines due to a challenging macro environment. Despite these challenges, the company is focused on improving its market strategy and financial stability.
Q2-2025 Updates
Positive Updates
Record Level of Lead Growth
AirSculpt Technologies achieved a record level of lead growth and meaningful increase in consultation volume during the second quarter.
Debt Reduction
The company paid down $16 million in debt and has no borrowings on the revolving credit facility at the end of the quarter, improving financial flexibility.
Cost Reduction Plan Impact
Adjusted EBITDA improved by $2 million from Q1 2025 due to increased revenue and meaningful impact from cost reduction efforts.
Reduction in Customer Acquisition Costs
Customer acquisition cost for the quarter decreased to $2,905 per case from $3,325 in the prior year quarter, marking the first decrease since going public.
Negative Updates
Revenue Decline
Revenue for the second quarter was $44 million, a decline of 13.7% from the second quarter of 2024, driven by lower case volume and a challenging macro environment.
Same-Store Revenue Decline
Same-store revenue declined approximately 22% over the prior year quarter, reflecting challenges in consumer spending.
Case Volume Decline
Case volume declined by 14.1% to 3,392, influenced by the challenging market environment and softness in consumer spending.
Company Guidance
In the second quarter of fiscal 2025, AirSculpt Technologies reported a revenue of $44 million, marking a 13.7% decline from the prior year, driven by a challenging macro environment and lower case volumes. The average revenue per case remained steady between $12,000 and $13,000, with a total of 3,392 cases performed. Despite these challenges, the company achieved a record level of lead growth and an increase in consultation volume. Adjusted EBITDA was $5.8 million, representing a margin of 13.3%, slightly down from 13.5% in the second quarter of 2024. AirSculpt successfully reduced its debt by $16 million, ending the quarter with no borrowings on its revolving credit facility. Looking forward, the company reiterated its annual guidance, projecting fiscal 2025 revenue between $160 million and $170 million, and adjusted EBITDA between $16 million and $18 million. The guidance accounts for the current economic conditions and consumer spending uncertainties but does not anticipate a downturn in the economy.

Airsculpt Technologies Financial Statement Overview

Summary
Airsculpt Technologies faces significant financial challenges, marked by declining revenues, persistent losses, and negative cash flow metrics. Despite a stable balance sheet with manageable leverage, the negative cash flow and profitability metrics present risks to financial health.
Income Statement
45
Neutral
Airsculpt Technologies shows declining revenue growth with a negative trend in profitability. The TTM data reveals a gross profit margin of 58.0%, but the company struggled with a net loss, leading to a negative net profit margin of -9.95%. The EBIT margin is also negative at -8.38%, indicating operational challenges. Although EBITDA margin is positive at 7.36%, it reflects a significant decline from previous periods, indicating pressure on core earnings.
Balance Sheet
50
Neutral
The balance sheet indicates a moderate level of stability with a debt-to-equity ratio of 0.43 in the TTM period, suggesting manageable leverage. However, the return on equity is negative due to net losses, which is a concern. The equity ratio is 38.05%, highlighting a balanced structure, yet the overall health is impacted by persistent losses.
Cash Flow
40
Negative
The cash flow statement shows a negative free cash flow in the TTM period, reflecting cash outflows that pressure liquidity. The operating cash flow to net income ratio is negative due to losses, and free cash flow to net income ratio is also negative, indicating strain in converting profits to cash. This could pose a risk if the trend continues.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue165.11M180.35M195.92M168.79M133.31M62.77M
Gross Profit47.21M108.97M121.91M106.01M88.78M39.30M
EBITDA18.80M10.07M19.74M3.52M23.05M15.67M
Net Income-14.51M-8.25M-4.48M-14.68M10.55M5.75M
Balance Sheet
Total Assets198.37M210.00M204.02M200.76M200.55M179.61M
Cash, Cash Equivalents and Short-Term Investments8.19M8.23M10.26M9.62M25.35M10.38M
Total Debt0.00105.05M99.67M107.65M100.58M49.77M
Total Liabilities107.21M130.71M120.03M129.99M117.03M55.93M
Stockholders Equity91.16M79.29M83.99M70.77M83.53M123.68M
Cash Flow
Free Cash Flow-3.88M-2.66M14.04M11.53M19.52M10.27M
Operating Cash Flow4.54M11.35M23.96M24.45M26.63M13.96M
Investing Cash Flow-10.59M-14.01M-9.92M-12.92M-7.12M-3.69M
Financing Cash Flow-1.48M630.00K-13.39M-27.26M-4.55M-5.02M

Airsculpt Technologies Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6.03
Price Trends
50DMA
5.22
Positive
100DMA
3.85
Positive
200DMA
4.80
Positive
Market Momentum
MACD
0.34
Positive
RSI
55.44
Neutral
STOCH
63.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIRS, the sentiment is Positive. The current price of 6.03 is above the 20-day moving average (MA) of 5.80, above the 50-day MA of 5.22, and above the 200-day MA of 4.80, indicating a bullish trend. The MACD of 0.34 indicates Positive momentum. The RSI at 55.44 is Neutral, neither overbought nor oversold. The STOCH value of 63.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AIRS.

Airsculpt Technologies Risk Analysis

Airsculpt Technologies disclosed 74 risk factors in its most recent earnings report. Airsculpt Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Airsculpt Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (57)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$1.49B13.9511.19%2.61%19.16%31.92%
73
Outperform
$3.27B38.667.26%4.92%-7.34%
67
Neutral
$1.09B33.146.72%2.54%14.30%76.89%
60
Neutral
$2.84B-9.75%12.05%-432.59%
57
Neutral
£5.20B5.71-64.94%2.28%32.39%-7.18%
55
Neutral
$375.87M-16.47%-14.46%-315.81%
51
Neutral
$171.24M-27.25%-26.14%23.04%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AIRS
Airsculpt Technologies
6.02
2.08
52.79%
AMED
Amedisys
99.31
1.33
1.36%
NHC
National Healthcare
94.77
-23.71
-20.01%
USPH
US Physical Therapy
72.02
-16.01
-18.19%
JYNT
Joint
11.19
-1.14
-9.25%
SGRY
Surgery Partners
22.14
-7.84
-26.15%

Airsculpt Technologies Corporate Events

Executive/Board Changes
Airsculpt Technologies CAO Philip Bodie Resigns
Neutral
Aug 1, 2025

On July 29, 2025, Philip Bodie resigned from his position as Chief Accounting Officer at Airsculpt Technologies, with his resignation taking effect on August 1, 2025.

The most recent analyst rating on (AIRS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Airsculpt Technologies stock, see the AIRS Stock Forecast page.

Executive/Board ChangesPrivate Placements and FinancingBusiness Operations and StrategyFinancial Disclosures
AirSculpt Technologies CFO Retirement Announcement
Neutral
Aug 1, 2025

AirSculpt Technologies reported its second quarter fiscal 2025 results, highlighting a narrowed year-over-year revenue decline and increased consumer interest despite a decrease in case volume and revenue compared to the previous year. The company is piloting new offerings such as skin tightening and expanded financing options, and it has strengthened its balance sheet by reducing debt following a common stock offering. Dennis Dean, the CFO, announced his retirement, but will remain in his role until a successor is appointed, ensuring a smooth transition.

The most recent analyst rating on (AIRS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Airsculpt Technologies stock, see the AIRS Stock Forecast page.

Private Placements and FinancingBusiness Operations and Strategy
Airsculpt Technologies Completes $13.8 Million Public Offering
Positive
Jun 11, 2025

On June 9, 2025, AirSculpt Technologies entered into an underwriting agreement with Leerink Partners to sell 3,160,000 shares of common stock in a public offering, with an option for an additional 474,000 shares, which was fully exercised. The offering closed on June 11, 2025, raising approximately $13.8 million. The company plans to use the proceeds to prepay part of its outstanding debt and for general corporate purposes. Vesey Street Capital Partners, the company’s largest stockholder, purchased 1,000,000 shares. This move is expected to impact AirSculpt’s financial strategy by reducing debt and providing capital for business opportunities.

The most recent analyst rating on (AIRS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Airsculpt Technologies stock, see the AIRS Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Airsculpt Technologies Elects Directors at Annual Meeting
Neutral
May 8, 2025

On May 7, 2025, AirSculpt Technologies held its annual meeting of stockholders where two Class I directors, Yogi Jashnani and Daniel Sollof, were elected for a three-year term. Additionally, Grant Thornton was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, indicating continued stability in the company’s governance and financial oversight.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 02, 2025